FY2026 Earnings Forecast for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Leerink Partnrs dropped their FY2026 earnings estimates for shares of IQVIA in a report released on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $12.46 per share for the year, down from their previous estimate of $12.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2027 earnings at $13.78 EPS.

Several other equities analysts also recently weighed in on IQV. Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Robert W. Baird cut their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Trading Up 1.6 %

Shares of IQVIA stock opened at $197.57 on Thursday. The firm has a market cap of $35.86 billion, a PE ratio of 25.93, a P/E/G ratio of 1.97 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The business’s fifty day moving average is $223.40 and its two-hundred day moving average is $227.35.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. PGGM Investments raised its holdings in shares of IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares during the period. Simplify Asset Management Inc. lifted its holdings in IQVIA by 67.8% in the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the last quarter. Quadrature Capital Ltd acquired a new position in IQVIA in the first quarter valued at approximately $3,365,000. Raymond James & Associates boosted its position in IQVIA by 0.7% during the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the period. Finally, Versor Investments LP bought a new position in IQVIA during the 3rd quarter worth $1,328,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.